New drug ARO-AAT shows promise in early safety trial for rare lung disease
NCT ID NCT03362242
First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 26 times
Summary
This early-stage study tested the safety and how the body processes ARO-AAT in 45 healthy adults. The drug aims to lower abnormal protein levels that cause lung and liver damage in people with Alpha-1 Antitrypsin Deficiency. By focusing on safety first, this trial lays groundwork for future studies in patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPHA 1-ANTITRYPSIN DEFICIENCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site 1
Grafton, Auckland, 1010, New Zealand
Conditions
Explore the condition pages connected to this study.